Skip to Content

Zalbin Approval Status

  • FDA approved: No
  • Brand name: Zalbin
  • Generic name: albinterferon alfa-2b
  • Company: Human Genome Sciences, Inc.
  • Treatment for: Hepatitis C

Zalbin (albinterferon alfa-2b) is a genetic fusion of human albumin and interferon alfa intended for the treatment of chronic hepatitis C.

In October 2010, Human Genome Sciences, Inc. (HGS) announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for Zalbin (albinterferon alfa-2b). HGS and Novartis have decided not to develop Zalbin further.

Development Status and FDA Approval Process for Zalbin

Oct  5, 2010Human Genome Sciences Receives Complete Response Letter from FDA on Zalbin BLA for Chronic Hepatitis C
Jun 14, 2010Human Genome Sciences Announces Preliminary Feedback From FDA on Zalbin BLA for Chronic Hepatitis C
Nov 25, 2009Human Genome Sciences Submits Biologics License Application to FDA for Zalbin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.